Published • loading... • Updated
MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S.
- Medipost has secured FDA agreement to conduct a single pivotal Phase 3 study for CARTISTEM® in the U.S. for knee osteoarthritis treatment.
- This agreement aims to accelerate CARTISTEM®'s U.S. development timeline and improve Medipost's financial efficiency.
- The company expects to reduce clinical development time and costs, allowing earlier Biologics License Application filing and faster U.S. market entry.
- Medipost leveraged successful Phase 3 clinical data from South Korea and Japan to gain FDA agreement, according to Antonio Lee.
Insights by Ground AI
46 Articles
46 Articles
Daily Journal+45 Reposted by 45 other sources
MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S.
SEOUL, South Korea, June 3, 2026 /PRNewswire/ -- MEDIPOST, a fully integrated commercial stage cell therapy biotechnology company, announced today that it has secured the FDA's agreement to conduct a single pivotal Phase 3 study for CARTISTEM® in the U.S.…
·Cherokee County, United States
Read Full ArticleCoverage Details
Total News Sources46
Leaning Left10Leaning Right6Center15Last UpdatedBias Distribution49% Center
Bias Distribution
- 49% of the sources are Center
49% Center
L 32%
C 49%
R 19%
Factuality
To view factuality data please Upgrade to Premium
